Pregabalin Capsule
Product Images NDC 80425-0160

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 80425-0160). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Pharmacy Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig 1

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares four groups: Pregabalin 300 mg three times a day, Pregabalin 150 mg three times a day, Pregabalin 25 mg three times a day, and placebo. The graph indicates higher percent improvement in pain correlates with a higher percentage of patients improved for the active treatment groups compared to placebo.*

FDA Label Image

Fig 10

A Kaplan-Meier curve comparing the estimated percentage of subjects without LTR over a 180-day period for Pregabalin versus Placebo groups. The graph shows time in days on the x-axis and the estimated percentage of subjects without LTR on the y-axis, with separate lines representing Pregabalin and Placebo.*

FDA Label Image

Fig 11

A line graph comparing the percent of subjects improved versus percent improved from baseline to Week 12 BOCF for two groups: Pregabalin and Placebo. The x-axis represents the percent improved from baseline to Week 12 BOCF, and the y-axis shows the percent of subjects improved. The graph includes vertical reference lines at approximately 30, 50, and 70 percent improvement.*

FDA Label Image

Fig 12

A line graph displaying the percent of subjects improved versus the percent improvement from baseline to Week 16 BOCF. It compares Pregabalin and Placebo groups, with Pregabalin showing a higher percentage of subjects improved across the range. The x-axis represents percent improvement, and the y-axis represents the percent of subjects improved.*

FDA Label Image

Fig 2

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin 100 mg three times a day and placebo. The vertical axis shows the percent of patients improved, and the horizontal axis shows percent improvement in pain from baseline. The graph illustrates greater patient improvement with Pregabalin compared to placebo across different levels of pain improvement.*

FDA Label Image

Fig 3

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares four groups: Pregabalin 300 mg twice daily, Pregabalin 150 mg twice daily, Pregabalin 75 mg twice daily, and placebo, illustrating their relative efficacy in pain improvement over a range of improvement percentages.*

FDA Label Image

Fig 4

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline. It includes three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph shows trends in pain improvement across these groups.*

FDA Label Image

Fig 5

A line chart showing the percent of patients improved relative to percent improvement in pain from baseline, comparing Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The vertical axis represents the percent of patients improved, and the horizontal axis shows percent improvement in pain from baseline.*

FDA Label Image

Fig 6

Bar charts showing responder rates in two clinical studies (Study E1 and Study E3) comparing placebo and various doses of pregabalin. The vertical axis represents responder rates (%) and the horizontal axis lists placebo and pregabalin doses (ranging from 50 mg/day to 600 mg/day) with dosing frequencies (BID or TID). Statistically significant increases versus placebo are noted for higher doses.*

FDA Label Image

Fig 7

A line graph depicting seizure reduction as median percent change from baseline across different doses (0, 150, 300, and 600 mg/day) of Pregabalin from three studies (E1 BID, E2 TID, and E3 BID/TID). The graph shows increasing seizure reduction with higher doses and includes significant p-values indicating statistical relevance for changes from placebo.*

FDA Label Image

Fig 9

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin doses of 300 mg, 450 mg, and 600 mg daily to placebo. The graph shows the relationship of pain improvement across different dose levels over a range from 0 to 100 percent.*

FDA Label Image

Pregabalin 300mg Cap Qty 90 Ndc 80425 0160

Label for Pregabalin 300 mg capsules, pack of 90, from Advanced Rx Pharmacy of Tennessee, LLC. Includes NDC 80425-0160, lot number, expiration date, and storage instructions. Contains a QR code and contact information for the labeler in Nashville, TN.*

FDA Label Image

Structure

Chemical structure of Pregabalin, showing its molecular formula with a carboxylic acid group (CO2H) and an amino group (NH2) attached to a carbon chain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.